Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1577

1.

Purity assessment of recombinant human granulocyte colony-stimulating factor in finished drug product by capillary zone electrophoresis.

Benković G, Skrlin A, Madić T, Debeljak Z, Medić-Šarić M.

Electrophoresis. 2014 Jun 9. doi: 10.1002/elps.201300552. [Epub ahead of print]

PMID:
24913917
[PubMed - as supplied by publisher]
2.

Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF.

Reményi P, Gopcsa L, Marton I, Réti M, Mikala G, Pető M, Barta A, Bátai A, Farkas Z, Borbényi Z, Csukly Z, Bodó I, Fábián J, Király A, Lengyel L, Piukovics K, Torbágyi E, Masszi T.

Adv Ther. 2014 Apr;31(4):451-60. doi: 10.1007/s12325-014-0114-z. Epub 2014 Apr 1.

PMID:
24687301
[PubMed - in process]
3.

"Grastims" and fatal capillary leak syndrome.

[No authors listed]

Prescrire Int. 2014 Feb;23(146):46. No abstract available.

PMID:
24678521
[PubMed - indexed for MEDLINE]
4.

Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.

Fust K, Li X, Maschio M, Barron R, Weinstein MC, Parthan A, Walli-Attaei M, Chandler DB, Lyman GH.

Gynecol Oncol. 2014 Jun;133(3):446-53. doi: 10.1016/j.ygyno.2014.03.014. Epub 2014 Mar 19.

PMID:
24657302
[PubMed - indexed for MEDLINE]
5.

Doping control analysis of filgrastim in equine plasma and its application to a co-administration study of filgrastim and recombinant human erythropoietin in the horse.

Ho EN, Kwok WH, Lau MY, Wong AS, Lam KK, Stewart BD, Wan TS.

J Chromatogr A. 2014 Apr 18;1338:92-101. doi: 10.1016/j.chroma.2014.02.064. Epub 2014 Feb 28.

PMID:
24636755
[PubMed - in process]
6.

Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen®.

Crobu D, Spinetti G, Schrepfer R, Tonon G, Jotti GS, Onali P, Dedoni S, Orsini G, Di Stefano A.

BMC Pharmacol Toxicol. 2014 Feb 21;15(1):7. doi: 10.1186/2050-6511-15-7.

PMID:
24555723
[PubMed - in process]
Free PMC Article
7.

The clinical use of granulocyte-colony stimulating factor.

Shah J, Welsh SJ.

Br J Hosp Med (Lond). 2014 Feb;75(2):C29-32. Review. No abstract available.

PMID:
24521833
[PubMed - indexed for MEDLINE]
8.

Cladribine in the treatment of acute myeloid leukemia.

Robak T, Wierzbowska A.

Leuk Res. 2014 Apr;38(4):425-7. doi: 10.1016/j.leukres.2014.01.005. Epub 2014 Jan 14. No abstract available.

PMID:
24485872
[PubMed - indexed for MEDLINE]
9.

A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial.

Hertzberg M, Matthews JP, Stone JM, Dubosq MC, Grigg A, Ellis D, Benson W, Browett P, Horvath N, Januszewicz H, Abdi E, Green M, Bonaventura A, Marlton P, Cannell P, Wolf M; ALLG.

Am J Hematol. 2014 May;89(5):536-41. doi: 10.1002/ajh.23684. Epub 2014 Feb 21.

PMID:
24481640
[PubMed - indexed for MEDLINE]
10.

Cost minimization analysis of two treatment regimens for low-risk rhabdomyosarcoma in children: a report from the Children's Oncology Group.

Russell H, Swint JM, Lal L, Meza J, Walterhouse D, Hawkins DS, Okcu MF.

Pediatr Blood Cancer. 2014 Jun;61(6):970-6. doi: 10.1002/pbc.24950. Epub 2014 Jan 22.

PMID:
24453105
[PubMed - indexed for MEDLINE]
11.

Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.

Jaglal MV, Duong VH, Bello CM, Al Ali NH, Padron E, Fernandez HF, List AF, Lancet JE, Komrokji RS.

Leuk Res. 2014 Apr;38(4):443-6. doi: 10.1016/j.leukres.2013.12.010. Epub 2013 Dec 25.

PMID:
24439565
[PubMed - indexed for MEDLINE]
12.

Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.

Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Blum KA, Powell BL, Shea TC, Nattam S, Hoke E, Cheson BD, Larson RA; Alliance for Clinical Trials In Oncology (ACTION).

Br J Haematol. 2014 Apr;165(1):102-11. doi: 10.1111/bjh.12736. Epub 2014 Jan 15.

PMID:
24428673
[PubMed - indexed for MEDLINE]
13.

Safety of pegfilgrastim (neulasta) in patients with sickle cell trait/anemia.

Kasi PM, Patnaik MM, Peethambaram PP.

Case Rep Hematol. 2013;2013:146938. doi: 10.1155/2013/146938. Epub 2013 Dec 11.

PMID:
24396616
[PubMed]
Free PMC Article
14.

Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.

Pilorge S, Rigaudeau S, Rabian F, Sarkozy C, Taksin AL, Farhat H, Merabet F, Ghez S, Raggueneau V, Terré C, Garcia I, Renneville A, Preudhomme C, Castaigne S, Rousselot P.

Am J Hematol. 2014 Apr;89(4):399-403. doi: 10.1002/ajh.23653. Epub 2014 Mar 7.

PMID:
24375467
[PubMed - indexed for MEDLINE]
15.

[Quality characteristics and non-clinical/clinical profile of Filgrastim BS injection syringe "Mochida"/"F"].

Oba S, Imada K, Tomomitsu M, Takedani H, Kaneko D.

Nihon Yakurigaku Zasshi. 2013 Dec;142(6):304-14. Review. Japanese. No abstract available.

PMID:
24334930
[PubMed - indexed for MEDLINE]
16.

The ability of filgrastim to mitigate mortality following LD50/60 total-body irradiation is administration time-dependent.

Farese AM, Brown CR, Smith CP, Gibbs AM, Katz BP, Johnson CS, Prado KL, MacVittie TJ.

Health Phys. 2014 Jan;106(1):39-47. doi: 10.1097/HP.0b013e3182a4dd2c.

PMID:
24276548
[PubMed - indexed for MEDLINE]
17.

Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.

Kamioner D, Fruehauf S, Maloisel F, Cals L, Lepretre S, Berthou C.

BMC Cancer. 2013 Nov 16;13:547. doi: 10.1186/1471-2407-13-547.

PMID:
24237790
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trial.

Paul M, Ram R, Kugler E, Farbman L, Peck A, Leibovici L, Lahav M, Yeshurun M, Shpilberg O, Herscovici C, Wolach O, Itchaki G, Bar-Natan M, Vidal L, Gafter-Gvili A, Raanani P.

Am J Hematol. 2014 Mar;89(3):243-8. doi: 10.1002/ajh.23622.

PMID:
24178750
[PubMed - indexed for MEDLINE]
19.

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer.

Rigter LS, Loo CE, Linn SC, Sonke GS, van Werkhoven E, Lips EH, Warnars HA, Doll PK, Bruining A, Mandjes IA, Vrancken Peeters MJ, Wesseling J, Gilhuijs KG, Rodenhuis S.

Br J Cancer. 2013 Dec 10;109(12):2965-72. doi: 10.1038/bjc.2013.661. Epub 2013 Oct 22.

PMID:
24149178
[PubMed - indexed for MEDLINE]
20.

Will biosimilars gain momentum?

Hirsch BR, Lyman GH.

J Natl Compr Canc Netw. 2013 Oct 1;11(10):1291-7. Review.

PMID:
24142828
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk